V ascular development is a multistep process that initially involves vasculogenesis, the process of de novo formation of the primitive vasculature from mesodermal precursors, and angiogenesis, that involves sprouting and remodeling of the primitive vasculature. 1 This is followed by vascular fate specification steps that define formation of arterial, venous, and lymphatic vasculatures. 2 This complex series of steps is regulated by several growth factors and their receptors. Among them are vascular endothelial growth factors (VEGFs), angiopoietins, and Notch receptors and their ligands, Dll4 and jagged-1. Any abnormalities in this sequence of events lead to either an outright failure of vascular development or formation of abnormally patterned vasculature. The later includes arterio-venous malformations, cranial cerebral malformations, and aneurysms among others. 
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Among the numerous growth factors that are involved in these phenomena, VEGF-A plays a particularly critical role and is involved both in formation of the initial primitive vascular plexus and in subsequent sprouting, remodeling, and fate specification steps. 4 VEGF-A signaling input is tightly controlled so much that deletion of even a single Vegfa allele results in embryonic lethality. 5, 6 VEGF-A signals via its 2 tyrosine kinase receptors (VEGFRs), Flt1 (VEGFR1) and Flk1 (VEGFR2), as well as a nonreceptor tyrosine kinase neuropilin-1 (Nrp1). Deletion of VEGFR2 is embryonically lethal because of almost complete failure of vasculogenesis, 7 whereas endothelial deletion of Nrp1 leads to multiple vascular abnormalities at a later stage of development.
8 VEGFR1 in this context is seen mainly as a negative regulator of VEGF-A signaling. Its knockout leads to embryonic lethality because of excessive vasculogenesis and angiogenesis. 9 Given the critical role that VEGF-A plays in vascular development and the tight control of its effective concentration range, much effort has been expanded to understand the mechanisms that regulate its expression. Several transcription factors have been implicated in control of endothelial-specific gene expressions, including homeobox protein B5, 10 zinc finger transcription factor GATA2, 11 basic helix-loop-helix transcription factor Tal1, 12 as well as the E26 transformationspecific (ETS) family and forkhead (Fox) family.
ETS genes appear particularly critical, as all known endothelial enhancers and promoters contain multiple ETSbinding sites. Furthermore, analysis of the human genome shows a strong association between ETS motifs and endothelial genes. 13 Among the 19 different ETS expressed by human endothelial cells, 2 have a particular importance as a regulator of endothelial cell development: Etv2 and Fli-1. Etv2 is expressed at the early stages of murine vascular development and is extinguished by E10.5. Mice with homozygous disruption of Etv2 expression die at midgestation with a complete lack of endothelial progenitors, blood islands, and vessels as shown by the absence of key vascular markers, such as Flk1, Pecam, and Tie-2.
14 Fli-1 is also expressed early in hematopoietic and endothelial cells and seems to be upstream of most transcriptional factors. 15 But unlike Etv2, deletion of Fli-1 in mice leads to embryonic lethality consecutive to hemorrhages and loss of vascular integrity and defects in hematopoietic although endothelial specification is not affected. 16 Another family of transcription factors critical to endothelial gene expression is Fox, with FoxF1 and FoxH1 have been established as key regulators of endothelial genes' expression. A global FoxF1 knockout in mice is lethal by midgestation, with the embryos demonstrating several defects, including, notably, a lack of vasculogenesis. 17 In contrast, FoxH1 has an inhibitory function in vascular specification, as its overexpression in zebrafish impairs vascular development and downregulates flk1 expression. 18 As important as individual transcription factors are, interactions among them are probably critical to fine specification of vascular development. One such well characterized interaction is the role played by the FOX:ETS motif, which consists of an ETS site and noncanonical FOX site. 13 This motif is highly associated with endothelial genes, Tal1, Tie2, Flk1, and VE-cadherin among them. 13 Although Etv2 or FoxC2 alone weakly activate genes with this motif in their enhancers or promoters, the activation is much stronger that they bind simultaneously. 13, 19 Despite these advances, our knowledge of transcriptional regulators of key endothelial genes is incomplete. In this issue of Circulation research, Ren and collaborators describe the role of endothelial FoxF1 in the development of embryonic vasculature. 20 Although the involvement of FoxF1 in vasculogenesis was already suggested by studies in the global Foxf1 knockout mice, 17 the mechanism behind that observation was not yet elucidated.
FoxF1 is expressed in endothelial cell precursors between E8.5 and E12.5 and in pulmonary, yolk sac, and placental endothelial cells at E13.5. Endothelial-specific deletion of the transcription factor results in a reduction in vascular branching in the yolk sac and placenta, as well as in the lung of the embryo proper and retinas of the newborn mice. Other prominent abnormalities include growth retardation, cardiac ventricular hypoplasia, and endocardia cushions defect. Overall, the deletion leads to a progressive lethality between E13.5 and E16.5. Although it is hard to evaluate growth retardation and organ hypoplasia in the presence of yolk sac and placenta vascular defects, it is tempting to speculate that they are associated with reduced vascular tissue density and are consistent with the notion that vascular density determines organ size. 21 On the molecular level, the loss of endothelial FoxF1 induced a profound reduction in expression of several endothelial-specific genes encoding VEGFR1, VEGFR2 and R 2 , PECAM, etc. At the same time, there was a marked increase in Dll4 and Ang2 expression. The reduction in VEGFR2 expression and the consequent decrease in VEGF-driven ERK activation and a profound decline in ephrin B2 and Sox17 levels are particularly interesting as these have been linked to the arterial fate specification program. [22] [23] [24] At the same time, a marked increase in Dll4 would be expected to result in increased Notch signaling, leading to decreased vascular branching, 25, 26 whereas elevated Ang2 levels may result in vascular destabilization. 27, 28 Some or all of these mechanisms may account for alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV) observed in patients with FOXF1 mutations.
ACD/MPV is characterized by a defect in the development of pulmonary vasculature, leading to severe respiratory distress and pulmonary hypertension in few hours after birth and in most cases death within the first month of the patient life. 29 Mutations or deletion in FOXF1 gene occur in ≈40% of ACD/MPV cases. 30 Mice with endothelial FOXF1 deletion had decreased pulmonary capillary density, an ACD/ MVP feature, albeit not a full-blown syndrome. It is tempting to speculate that this is likely because of early mortality and that a less severe defect in FoxF1-driven pathway would lead to these findings.
This interesting work raises multiple questions, notably regarding the regulation of FoxF1 expression in endothelial cells. Indeed, FoxF1 is not expressed in all endothelial cells, and its expression level varies in different developmental stages and tissues. 31 Although sonic hedgehog has been described as an inducer of FoxF1 expression, 32 its role in this pathway has not been conclusively established. It would be interesting to compare endothelial knockout of sonic hedgehog receptor Patched-1 with the phenotype observed in this study. On a molecular level, it is unclear what ETS family member FoxF1 interacts with or whether it truly acts alone. Finally, as already discussed, Foxf1-deficient mice exhibit some but not all features of ACD/MPV. A study in somewhat older animals with the knockout induced by a Cre driver with a better activity in the lung vasculature than Pdgfb-CreER T2 used in the present study would go a long way clarifying that.
The latter considerations bring us to the vexing issue of endothelial Cre driver choices. In the case of the article in question, the authors performed most of the work using Tie2-Cre. This was clearly noticed by an eagle-eyed reviewer who asked the authors to repeat the study with another endothelial Cre driver because Tie2-Cre is expressed in a certain population of hematopoietic and mononuclear cells, and thus some of the observed effects may be because of the effect of the target gene knockout in these cell populations rather than in the endothelium proper. Indeed, such has likely been the fate of a number of recently published studies, including (in the interest of full disclosure) one from our laboratory. 33 Remarkably, as far as we are aware, there is not a single published study that demonstrates a difference in a vascular development phenotype with the use of Tie2 versus any other Cre. It is entirely possible, of course, that when such a difference was detected, Tie2-Cre data were simply dropped from the article. Nevertheless, given this state of knowledge, it seem unreasonable to demand new, expensive, and time-consuming studies when the original work was done with Tie2, unless there is a sufficiently justified and strong concern that nonendothelial Tie2 + cell populations do really matter. It would seem reasonable to simply acknowledge the limitations of Tie2-Cre system. On the contrary, there are now much better endothelial-specific Cre lines, Pdgfb-CreER T2 and Cdh5-CreER T2 among them. 34 On yet another hand, Pdgfb-Cre used in the present study is very effective in the retina but much less so in other vascular beds. So choices do matter but so does the common sense.
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